Suven Life Sciences to showcase CNS pipeline at BIO Convention 2026

SUVEN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

-4.0%1-day move

₹269.00

prior close

₹263.50

base price

In-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

+0.4+0.7+1.1+1.0-4.0-5.2-0.6+3.8+4.3+12.4+29.7+19.7——

Up moveDown movePending

AI summary

Suven Life Sciences will attend BIO International Convention 2026 in San Diego (June 22-25) at Booth 6154, with 62 pre-scheduled partnering meetings planned. The company will showcase its CNS pipeline including Ropanicant (positive Phase-2b results for depression, Phase-3 in H1-2027), Masupirdine (Phase-3 AWAKE 95% enrolled for Alzheimer's agitation, results Q2-2027), and Samelisant (Phase-3 for narcolepsy, results Q2-2028). Goal is to explore out-licensing and co-development deals with global pharma.

Likely market impact

Conference participation with 62 partner meetings may lead to licensing deals. Strong Phase-2b Ropanicant data boosts partnering appeal.